Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 8/20 | 1.00 |
| ▸ | PTPRA | P18433 | 1/20 | 0.54 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.47 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.47 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.47 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.47 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piridronic Acid SCHEMBL634964 | 0.89 | FDPS (0.79) | FDPSPTPRAGRIN2DGRIN3BGRIN1 | |
| SCHEMBL8165506 | 0.83 | FDPS (0.70) | FDPSPTPRAGRIN2DGRIN3BGRIN1 | |
| Piridronic Acid SCHEMBL4614564 | 0.83 | FDPS (0.69) | FDPSPTPRAGRIN2DGRIN3BGRIN1 | |
| SCHEMBL8167866 | 0.82 | FDPS (0.69) | FDPSPTPRAGRIN2DGRIN3BGRIN1 | |
| Piridronic Acid SCHEMBL9083495 | 0.80 | FDPS (0.67) | FDPSPTPRAGRIN2DGRIN3BGRIN1 | |
| SCHEMBL8170605 | 0.79 | FDPS (0.65) | FDPSPTPRAGRIN2DGRIN3BGRIN1 | |
| Pyridin-2-Ylmethylphosphonic Acid SCHEMBL31467550 | 0.79 | FDPS (0.65) | FDPSALDH1A1KCNA5SMN1; SMN2 | |
| Pyridin-2-Ylmethylphosphonic Acid SCHEMBL1585351 | 0.79 | FDPS (0.65) | FDPSALDH1A1KCNA5SMN1; SMN2 | |
| SCHEMBL8715030 | 0.78 | FDPS (0.64) | FDPSPTPRAGRIN2DGRIN3BGRIN1 | |
| SCHEMBL8166906 | 0.78 | FDPS (0.63) | FDPSPTPRAGRIN2DGRIN3BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 646 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117940155-A | Immunogenic composition, preparation method and application thereof | 清华大学 | 2024-04-26 | — | — | CN | claimed |
| WO-2023036249-A1 | IMMUNOGENIC COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 清华大学 | 2023-03-16 | — | — | WO | claimed |
| US-11173169-B2 | Self-emulsifying formulation of bisphosphonates and associated dosage forms | Halo Science LLC (US) | 2021-11-16 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-7915239-B2 | Treating lameness with an osseous and/or articular component which appear in a person or animal not suffering from fractures or arthritis; horses; veterinary medicine; bone disorders, osteoarthritis | CEVA SANTE ANIMALE (FR) | 2011-03-29 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| EP-1446115-B1 | CYANOALKYLAMINO DERIVATIVES AS PROTEASE INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2008-02-27 | — | — | EP | claimed |
| EP-1248612-B1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2008-02-27 | — | — | EP | claimed |
| EP-1120117-B1 | Method of increasing the production of eggs and strengthening eggshells in poultry | CEVA SANTE ANIMALE (FR) | 2007-09-12 | — | — | EP | claimed |
| WO-1997012619-A1 | METHOD OF TREATING THE NAVICULAR DISEASE IN HORSES | NOVARTIS AG (CH) | 1997-04-10 | — | — | WO | claimed |
| US-5583122-A | TREATING DISEASES ASSOCIATED WITH ABNORMAL CALCIUM AND PHOSPHATE METABOLISM | THE PROCTER & GAMBLE COMPANY (US) | 1996-12-10 | — | — | US | claimed |
| EP-0600834-A1 | Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing | CIBA-GEIGY AG (CH) | 1994-06-08 | — | — | EP | claimed |
| EP-0550385-A1 | Oral pharmaceutical compositions containing derivatives of methane-diphosphonic acid and 18-crown-6 ethers | CIBA-GEIGY AG (CH) | 1993-07-07 | — | — | EP | claimed |
| US-5133972-A | TOPICALLY ADMINISTRABLE PHARMACEUTICAL PREPARATIONS | CIBA-GEIGY CORPORATION (US) | 1992-07-28 | — | — | US | claimed |
| EP-0336851-B1 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION CONTAINING A DIPHOSPHONIC ACID DERIVATIVE | ELF SANOFI (FR) | 1992-03-18 | — | — | EP | claimed |
| EP-0186405-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING GEMINAL DIPHOSPHONATES | THE PROCTER & GAMBLE COMPANY (US) | 1991-03-06 | — | — | EP | claimed |
| EP-0407344-A2 | Pharmaceutical preparation for topical application | CIBA-GEIGY AG (CH) | 1991-01-09 | — | — | EP | claimed |
| US-4980171-A | AND SODIUM LAURYL SULFATE; EXCELLENT BIOAVAILABILITY; BONE DISORSERS, ANTIARTHRETIC | SOCIETE ANONYME DITE : SANOFI (FR) | 1990-12-25 | — | — | US | claimed |
| EP-0186405-A2 | Pharmaceutical compositions containing geminal diphosphonates | THE PROCTER & GAMBLE COMPANY (US) | 1986-07-02 | — | — | EP | claimed |